['multiple myeloma']
['elotuzumab', 'pomalidomide', 'dexamethasone']

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  ≥ 2 prior lines of therapy which must have included at least 2 consecutive cycles of
             lenalidomide and a proteosome inhibitor alone or in combination

          -  Documented refractory or relapsed and refractory multiple myeloma

          -  Refractory to proteosome inhibitor and lenalidomide, and to last treatment

          -  Relapsed and refractory patients must have achieved at least a partial response to
             previous treatment with proteosome inhibitor or lenalidomide, or both, but progressed
             within 6 months, and were refractory to their last treatment

          -  Measurable disease at screening

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

        Exclusion Criteria:

          -  Active plasma cell leukemia

          -  Prior treatment with pomalidomide

          -  Unable to tolerate thromboembolic prophylaxis while on the study

          -  Prior autologous stem cell transplant within 12 weeks

          -  Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C
      